Clinical Trial

A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

Study acronym: SPARTAN
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To determine the nephroprotective potential of treatment with sparsentan in (1: Cohort A) patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy, and in (2: Cohort B) patients with recurrent IgAN following kidney transplantation.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-12-08; most recent amendment 2026-05-29.
Status change: Active, Not Recruiting → Recruiting 2026-05-29
Status change: Recruiting → Active, Not Recruiting 2023-10-23
Trial Details
NCT Number NCT04663204
Lead Sponsor University of Leicester
Collaborators: Travere Therapeutics, Inc.
Conditions Immunoglobulin A Nephropathy, Kidney Diseases, Glomerulonephritis, IGA, Glomerulonephritis, Autoimmune Diseases, Immune System Diseases
Enrollment 24 participants
Start Date 2020-12-10
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-03